Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0I5GS
|
|||
| Drug Name |
CAR.CD30 cells
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Immune System disease [ICD-11: 4A01-4B41] | Phase 1/2 | [1], [2] | |
| Immunoproliferative disorder [ICD-11: 2B32; ICD-10: D47.9] | Phase 1/2 | [1], [2] | ||
| Lymphatic disease [ICD-11: BD9Z] | Phase 1/2 | [1], [2] | ||
| Lymphoma [ICD-11: 2A80-2A86; ICD-9: 202.8, 208.9] | Phase 1/2 | [1], [2] | ||
| Neoplasm [ICD-11: 2A00-2F9Z] | Phase 1/2 | [1], [2] | ||
| Company |
UNC Lineberger Comprehensive Cancer Center
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Lymphocyte activation antigen CD30 (TNFRSF8) | Target Info | CAR-T-Cell-Therapy | [1], [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| NetPath Pathway | Leptin Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02663297) Administration of T Lymphocytes for Prevention of Relapse of Lymphomas | |||
| REF 2 | ClinicalTrials.gov (NCT02690545) Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.